Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alterity Therapeutics ADR ATHE

Healthcare Biotechnology
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the... see more

Recent & Breaking News (NDAQ:ATHE)

Alterity Therapeutics Prominently Featured at the International MSA Congress

GlobeNewswire May 12, 2025

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

GlobeNewswire May 7, 2025

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

GlobeNewswire May 5, 2025

Appendix 4C - Q3 FY25 Quarterly Cash Flow Report

GlobeNewswire April 30, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

GlobeNewswire April 28, 2025

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

GlobeNewswire April 10, 2025

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

GlobeNewswire April 3, 2025

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

GlobeNewswire March 27, 2025

Alterity Therapeutics Raises A$40.0 million in Placement

GlobeNewswire February 10, 2025

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

GlobeNewswire January 30, 2025

Appendix 4C - Q2 FY25 Quarterly Cash Flow Report

GlobeNewswire January 24, 2025

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

GlobeNewswire January 9, 2025

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

GlobeNewswire December 4, 2024

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

GlobeNewswire November 19, 2024

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

GlobeNewswire November 12, 2024

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

GlobeNewswire November 6, 2024

Appendix 4C - Q1 FY25 Quarterly Cash Flow Report

GlobeNewswire October 31, 2024

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

GlobeNewswire October 14, 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

GlobeNewswire October 11, 2024

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire October 2, 2024